Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established ...

A guide to the people and activist organizations who paved the way for Donald Trump's attacks on diversity practices in ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

Shares of Pfizer Inc. PFE shed 1.45% to $26.52 Friday, on what proved to be an all-around grim trading session for the stock ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...